- 癌癥檢測公司拓展全球市場-
Zila, Inc. （納斯達克GM股票代碼：ZILA）今天宣布公司已從一家臺灣公司President Medical Technologies, Inc.手中獲得在泛太平洋地區(qū)生產和銷售ViziLite(R)的權利。這一交易使Zila從ViziLite技術的被許可人成為ViziLite的所有權人之一，這些權利包括包括基礎專利技術以及全球銷售。

Zila正在執(zhí)行其將ViziLite Plus構建為口腔癌癥檢測新標準的計劃。ViziLite Plus是市面上用于可能導致癌癥的口腔異常情況早期檢測最為先進的技術。Zila的下一代口腔癌癥診斷產品，OraTest，目前正在進行三期臨床試驗。

Zila主席、首席執(zhí)行官兼總裁Douglas Burkett博士說：“口腔癌癥在泛太平洋地區(qū)是流行性致命疾病。本次交易為我們的癌癥檢測產品在泛太平洋地區(qū)銷售尋找戰(zhàn)略性合作伙伴鋪平了道路。我們的目標不僅僅是在美國的口腔醫(yī)院，而是最終在全球范圍內把ViziLite Plus樹立成為保健標準。”

在昨天的另一新聞發(fā)布會上， Zila宣布計劃收購Professional Dental Technologies ("Pro-Dentec(R)") 來增強公司在美國區(qū)域營銷其口腔癌癥檢測產品的能力。

關于口腔癌癥

口腔癌癥是全球范圍內最為致命的癌癥種類之一，居高死亡率很大程度上是由于約有三分之二的口腔癌癥患者直到晚期才被發(fā)現。如果能在早期檢測出口腔癌癥，病人的存活率在80%左右；而如果在晚期才被檢測出，存活率則會降低到20%。美國牙科協會表示雖然大部分的口腔癌癥患者是由于吸煙以及/或者飲酒過度而導致，但還有超過四分之一的患者從不吸煙，也沒有其他不良嗜好。

關于Zila, Inc.

Zila, Inc.總部位于鳳凰城，是一家最初專注口腔癌癥的領先癌癥檢測公司：

-- Zila Pharmaceuticals致力于將ViziLite(R) Plus構建成為可能導致癌癥的口腔異常狀況早期檢測新標準。

-- Zila Biotechnology致力于為下一代口腔癌癥診斷產品OraTest(R)獲得藥品注冊審批，同時進行癌癥檢測技術的其他應用開發(fā)，包括頸部和食管癌癥早期檢測產品。

有關Zila的更多信息，請訪問 www.zila.com 。

此新聞稿含有《1933年證券管理條例》第27節(jié)第一條和《1934年證券交易稅案》第21節(jié)第5條所規(guī)定的“前瞻性聲明”。這些前瞻性聲明很大程度上取決去Zila的預期或者未來事件的預測，會受到不準確假設、各種商業(yè)風險和已知、未知不確定因素的影響，其中大部分因素公司無法控制。因此，真實結果可能與本新聞稿中的前瞻性聲明大相徑庭。很多因素都可能導致這些差異，并將嚴重損害公司的收入、盈利狀況、現金流和資本需要。我們無法保證本新聞稿中所包含的前瞻性聲明將成為現實。有關可能影響Zila未來業(yè)績的風險因素的更多詳細描述，請參考Zila提交的2006年7月31日結束財年10-K表格。

聯系方式：Zila, Inc. Andrew Stevens, 602-266-6700 或者 投資者關系部門 投資者關系 Antima "Taz" Sadhukhan/Dian Griesel, 212-825-3210 或者 媒體： Bill Douglass, 212-825-3210

(BW)(AZ-ZILA)(ZILA) Zila, Inc. Adds Pacific Rim To ViziLite Market

- Cancer Detection Company Extends Global Reach -

PHOENIX--(BUSINESS WIRE)--Nov. 15, 2006--

Zila, Inc. (Nasdaq GM: ZILA) reported today that it has acquired the rights to manufacture and distribute ViziLite(R) in the Pacific Rim from President Medical Technologies, Inc., a Taiwanese company. This transaction completes the evolution of Zila from a licensee of the ViziLite technology to one of sole owner of all ViziLite rights, including the underlying patented technology and world-wide distribution.

Zila is executing its plan to establish ViziLite Plus as the new standard of care in oral cancer detection. ViziLite Plus is the most advanced technology on the market for the early detection of oral abnormalities that could lead to cancer. Zila's next generation oral cancer diagnostic product, OraTest, is currently proceeding through a Phase III clinical trial.

"Oral cancer is a prevalent and deadly disease within the Pacific Rim. This transaction paves the way for strategic alliances for the distribution of our cancer detection products within the Pacific Rim. It is our goal to establish ViziLite Plus as the standard of care, not only in dental offices across the United States, but ultimately around the world," stated Zila Chairman, CEO and President, Douglas Burkett, Ph.D.

In a separate release yesterday, Zila announced its plan to acquire Professional Dental Technologies ("Pro-Dentec(R)") in order to strengthen the Company's ability to market and sell its oral cancer detection products in the United States.

About Oral Cancer

Oral cancer is among the most deadly cancer types globally, largely owing to the fact that roughly two-thirds of all oral cancers are detected at advanced stage. When oral cancer is detected early, survival rates are about 80%; detected late, the survival rate falls to 20%. The American Dental Association says that while most cases of oral cancer affect people who use tobacco and/or drink heavily, more than a quarter of oral cancers occur in people who do not smoke and have no other risk factors.

About Zila, Inc.

Zila, Inc., headquartered in Phoenix, is a leading cancer diagnostic company initially focused on oral cancer:

-- Zila Pharmaceuticals is dedicated to establishing ViziLite(R) Plus as the new standard of care for the early detection of oral abnormalities that could lead to cancer.

-- Zila Biotechnology is focused on achieving regulatory approval for the next generation oral cancer diagnostic, OraTest(R), followed by the development of additional applications of its cancer detection technologies including products for the early detection of cervical and esophageal cancer.

For more information about Zila, visit www.zila.com .

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31,2006.

CONTACT: Zila, Inc. Andrew Stevens, 602-266-6700 or The Investor Relations Group Investor Relations: Antima "Taz" Sadhukhan/Dian Griesel, 212-825-3210 or Media: Bill Douglass, 212-825-3210

------轉載